Is the AstraZeneca share price still good value at £10?

The AstraZeneca share price has been a top FTSE 100 performer in recent years. Roland Head asks if he’s too late to buy.

| More on:
Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

FTSE 100 pharmaceutical giant AstraZeneca (LSE: AZN) has seen its share price rise by around 25% over the last 12 months. AstraZeneca shares have now doubled over the last five years.

Its growth has accelerated under chief executive Pascal Soriot. I’d like to own a slice of this market-leading business, but I need to be sure there’s still some value left for me. Here’s what I’ve decided.

Strong momentum

The Anglo-Swedish group’s sales rose by 26% to $33.4bn in 2021, excluding around $4bn of revenue from Covid-19 vaccine sales. I’ve ignored this as I don’t see this product as part of the firm’s ongoing business. At least, I hope it won’t be.

This revenue growth supported a 32% rise in adjusted earnings, which rose to $5.29 per share.

Soriot says the company had 13 blockbuster medicines in 2021 – those with sales of more than $1bn. This list included two new ones, Calquence and Fasenra.

These numbers suggest to me that Mr Soriot’s strategy of pursuing acquisitions alongside in-house drug development is really starting to pay off.

Growth has stayed strong so far this year. The group’s sales rose by 56% to $11.4bn during the first quarter, while adjusted earnings were 16% higher.

What’s the risk?

One thing that’s stopped me from buying AstraZeneca shares in recent years has been the company’s poor cash generation. Mr Soriot’s spending spree has been financed mostly by borrowed cash – net debt has risen from under $5bn to $24bn since 2014.

If the company had continued down this path, then a dividend cut might have been needed. Fortunately, I can see signs that its cash-guzzling days may soon be in the past.

The group’s free cash flow (surplus cash generated by the business) rose from $3.6bn to $5.6bn in 2021. Broker forecasts suggest this figure will rise to more than $7bn in 2022 and could top $10bn in 2023.

Here’s what I’m going to do

It looks like the big investments are starting to produce the best result of all – cash. However, AstraZeneca shares are still trading on 19 times forecast earnings, with a dividend yield of just 2.3%.

That’s a significant premium to FTSE 100 rival GSK, whose shares currently trade on 14 times earnings, with a prospective yield of 3.1%.

Although its earnings are expected to rise more quickly than those of GSK over the next few years, I’m not convinced that will be enough to justify the stock’s premium.

To help me decide, I’ve done some number crunching. What I found is that for me, AstraZeneca shares are already getting close to their fair value. I don’t think there’s enough value left for me to buy after the stock’s recent rebound.

On the other hand, GSK looks more promising to me. I plan to take a look at this stock over the coming weeks to see whether it could qualify for a slot in my portfolio. I’ll report back here with my findings.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Should I invest in the FTSE 100 – or try to beat it?

Our writer has the option of investing in a FTSE 100 tracker fund. So why does he choose to buy…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

£1,500 to invest in a Stocks and Shares ISA? Here’s how I’d do it

Our writer has been investing in his Stocks and Shares ISA. Here he details how he could put £1,500 in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

2 top FTSE 100 shares I’d buy before the market rebounds!

Christopher Ruane identifies a pair of FTSE 100 shares that have both tumbled in the past year and that he…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

Here’s why the next bull market may have already begun

The UK stock market has taken the Bank of England's interest rate hike in its stride and green shoots suggest…

Read more »

Gold medal
Investing Articles

No contest! Here’s my stock of the week

An update from this company offered some relief from the economic gloom. It's this Fool's stock of the week.

Read more »

Cogs turning against each other
Investing Articles

Scottish Mortgage shares are back on the rise: is now the time to jump onboard?

Scottish Mortgage shares have risen over 25% in the past 30 days. This Fool takes a look at why and…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Why do Lloyds shares seem so cheap?

Lloyds shares have been losing ground and now look cheap on some valuations. So why has our writer removed the…

Read more »

Investing Articles

How to invest in shares to help beat inflation

Soaring prices could well outstrip our investing returns this year. I think it's more important to find shares to beat…

Read more »